AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06646627
Drug: B7-H3CART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg
Trial: NCT06646445
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) according to the current guidelines, at the investigator's discretion.
Trial: NCT06244771
Drug: FMC-376
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04775706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, double-blind, placebo-controlled
Trial: NCT04948749
Drug: Aggressive medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
Trial: NCT04948749
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
Trial: NCT05674552
Drug: Exogenous ketone ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
Trial: NCT04927299
Drug: Losartan + hydrochlorothiazide in fixed dose
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
Trial: NCT06096116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
Trial: NCT05447429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
Trial: NCT04495387
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard adjuvat chemotherapy for reast and colo cancer
Trial: NCT05388188
Drug: sublingual sufentanil
RxNorm normalized name: sufentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dsuvia in patients with SCD VOC as a bridging medication.
Trial: NCT06375031
Drug: HR011408 injection; HR011408 injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum
Trial: NCT06375031
Drug: NovoRapid®; HR011408 injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum
Trial: NCT06375031
Drug: HR011408 injection Placebo; HR011408 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum
Trial: NCT05866562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
Trial: NCT04659863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Trial: NCT06244316
Drug: rhNGF concentration 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Trial: NCT06244316
Drug: rhNGF concentration 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Trial: NCT04950114
Drug: GFB-887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFB-887 is a potent, small molecule inhibitor of TRPC5.
Trial: NCT05609812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05657691
Drug: Xanamem™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
Trial: NCT05657691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
Trial: NCT01244607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single i.v. administration
Trial: NCT05435547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will take Placebo pre-operatively
Trial: NCT06339203
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mL
Trial: NCT05559931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion over 6 hours
Trial: NCT05528926
Drug: Treatment As Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
Trial: NCT00002398
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06305754
Drug: Acetaminophen (or equivalent)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as rescue medication per approved product label
Trial: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
Trial: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
Trial: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
Trial: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
Trial: NCT06173895
Drug: LY3454738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT06168383
Drug: HSK31679 80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
Trial: NCT06168383
Drug: HSK31679 160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
Trial: NCT06168383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral administration of placebo from Day 1 to Week 52.
Trial: NCT05103397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
Trial: NCT05366179
Drug: CAR.B7-H3T cells infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2).
Trial: NCT05274659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05303272
Drug: Mycophenolate Mofetil 500Mg Tab
RxNorm normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
Trial: NCT03602898
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03602898
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05068206
Drug: AK105 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK105 is programmed death 1（PD-1） monoclonal antibody
Trial: NCT05068206
Drug: CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
Trial: NCT05683470
Drug: RBS2418
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBS2418 will be administered orally at 200 mg two times per day (BID).
Trial: NCT05144984
Drug: NNC0480-0389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
Trial: NCT05144984
Drug: Placebo (NNC080-0389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
Trial: NCT05144984
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
Trial: NCT06020495
Drug: Standard hyponatremia treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic
Trial: NCT05418010
Drug: Tysabri Injectable Product
RxNorm normalized name: Tysabri Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
Trial: NCT05418010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
Trial: NCT05970497
Drug: KEYTRUDA ®( Pembrolizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (PD-1 immune checkpoint inhibitor)
Trial: NCT05444751
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence.
Trial: NCT06172010
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Trial: NCT05444751
Drug: SA + ESP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation.
Trial: NCT04807478
Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose, frequency and duration is a decision of the Investigator
Trial: NCT05402020
Drug: Inhaled corticosteroids (ICS)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS)
Trial: NCT05402020
Drug: Long-acting β2-agonists (LABA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-agonists (LABA)
Trial: NCT04765722
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Trial: NCT06463678
Drug: IVIEW-1201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
Trial: NCT06463678
Drug: NATACYN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
Trial: NCT04612699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05293509
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 IV-by vein
Trial: NCT05293509
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: by vein
Trial: NCT04905654
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Trial: NCT06364423
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Trial: NCT04457089
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
Trial: NCT06417320
Drug: ACEI, SGLT-2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)
Trial: NCT04991103
Drug: DaraVRD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22).
Trial: NCT05423249
Drug: Ascorbic Acid 500Mg Tab
RxNorm normalized name: ASCORBIC ACID 500MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
Trial: NCT05423249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo pill once daily
Trial: NCT06388187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Trial: NCT04950075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06349408
Drug: IBI3001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)
Trial: NCT06246396
Drug: Minocycline Hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline Hydrochloride 100 mg twice daily
Trial: NCT06246396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04649242
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 75 mg or 50 mg ODT placebo
Trial: NCT06210477
Drug: medical treatment for lower urinary tract symptoms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
Trial: NCT04669899
Drug: JTX-8064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05827653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a week, for 28 days
Trial: NCT04855799
Drug: Aquamin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Trial: NCT05592626
Drug: STAR0602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, intravenous infusion
Trial: NCT04983043
Drug: QiShen YiQi Dripping Pills placebo 3 bags
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Trial: NCT05314374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
Trial: NCT04882683
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg per kilogram per day for three months
Trial: NCT06198764
Drug: Coly Mycin M Injectable Product
RxNorm normalized name: Coly Mycin M Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coly Mycin M is the originally marketed colistimethate sodium for injection.
Trial: NCT05892770
Drug: Zinc gluconate supplement
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
Trial: NCT04698057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm